Xmoor Pharma has established a strategic collaboration with the Translational Research Office (TRO) and University College ...

MRM Health, a clinical-stage biopharmaceutical company developing microbiome-based therapeutics for inflammatory diseases and immuno-oncology, has announced its collaboration with Professor Emile ...

Finnish biotechnology company NADMED has announced the launch of the NADMED Award 2026 in the hope of generating new discoveries in the field of metabolomics.

JHU083 reduced tumour growth and triggered tumour cell death in mice Researchers from the Johns Hopkins Kimmel Cancer Center and Johns Hopkins Drug Discovery have revealed that a novel therapy can ...

A British inquiry into the use of chemotherapy to treat seriously ill cancer patients has found the treatment caused or hastened death in 27% of cases. A British inquiry into the use of chemotherapy ...

Foundation’s test to be used in Oxford-led blood biomarker trial The Food for the Brain Foundation’s Cognitive Function Test is set to play a central role in the UK-based ‘READ OUT’ trial, which is ...

SMC approves targeted therapy for patients with EGFR exon 20 insertion mutations Johnson & Johnson has welcomed the decision by the Scottish Medicines Consortium (SMC) to accept Rybrevant (amivantamab ...

Survey finds AI to enhance productivity and cut costs in the next 12 months AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, ...

US$5m payment from Bristol Myers Squibb marks progress in protein degradation partnership Evotec has received a US$5m milestone payment from Bristol Myers Squibb following the US Food and Drug ...

“The acquisition of Arthrosi allows us to expand our gout pipeline with a highly differentiated new asset. Pozdeutinurad has the potential to become the therapy of choice for patients who have ...

More than 37 million adults in the US are affected by migraine The US Food and Drug Administration (FDA) has approved Click Therapeutics’ CT-132 as the first prescription digital therapeutic for the ...

Santhera Pharmaceuticals has announced positive topline results from a long-term analysis of AGAMREE (vamorolone) in patients with Duchenne muscular dystrophy (DMD), including first data from the ...